Objective: To describe the challenges facing countries all over the world regarding the appropriate clinical use of genetics in their health care systems. Methods and Results: Aspects of the economic and social contexts in different countries which are of particular relevance to shaping the existing challenges are outlined. Issues which are relevant (but of different prominence) in all countries in providing genetic services are discussed. Conclusions: The challenges facing the provision of appropriate genetic services differ markedly in four major groups of countries. These challenges range from controlling inappropriate commercialization and the overuse of genetic approaches to putting in place even minimal basic community genetics services in countries where the infant mortality rate has fallen to a range where genetic and congenital disorders contribute substantially to ongoing handicap and early mortality.

1.
WHO Regional Office for Eastern Mediterranean: Community Control of Genetic and Congenital Disorders. EMRO Technical Publications Series No. 24. Alexandria, E.M.R.O., 1997.
2.
Modell B: Delivering genetic screening to the community. Ann Med 1997;29:591–599.
3.
Penchaszadeh VB: Delivery of genetic services in developing countries; in Khoury MJ, Burke W, Thomson EF (eds): Genetics and Public Health in the 21st Century. New York, Oxford University Press, 2000;pp 301–327.
4.
Baird PA: Boon or bane? Will we use genetics wisely? ISUMA Can J Policy Res 2001;2:94–101.
5.
Baird PA: Genetic technologies and achieving health for populations. Int J Health Serv 2000;30:407–424.
6.
Holtzman NA: Discovery, transfer, and diffusion of technologies for the detection of genetic disorders. Policy implications. Int J Technol Assess Health Care 1994;10:562–572.
7.
Hoffman JR, Wilkes M: Direct to consumer advertising of prescription drugs: An idea whose time should not come. BMJ 1999;318:1301–1302.
8.
Holmes AD, Bowen DJ, Bengal J: Genetic testing for breast cancer: An issue of money. Report on the Second National Conference on Genetics and the Public Health. Community Genet 1999;2:124.
9.
Harris R: Genetic services in Europe. A comparative study of 31 countries by the concerted action on genetic services in Europe. Eur J Hum Genet 1997;5(suppl 2):1–220.
10.
WHO Services for the Prevention and Management of Genetic Disorders and Birth Defects in Developing Countries: Report of a Joint WHO/WAOPBD Meeting. Geneva, WHO Human Genetics Program, WHO/HGN/GL/WAOPBD/99.1, 1999.
11.
McGovern MM, Benach MO, Wallenstein S, Desnick RJ, Keenlyside R: Quality assurance in molecular genetic testing laboratories. JAMA 1999;281:835–840.
12.
Giardiello FM, Brensinger JD, Petersen GM, Luce MC, Hylind LM, Bacon JA, Booker SV, Parker RD, Hamilton SR: The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336:823–827.
13.
Harris R, Lane B, Harris H, Williamson P, Dodge J, Modell B, Ponder B, Rodeck C, Alberman E: National Confidential Enquiry into counselling for genetic disorders by non-geneticists: General recommendations and specific standards for improving care. Br J Obstet Gynaecol 1999;106:658–663.
14.
Hunter A, Wright P, Cappelli M, Kasaboski A, Surh L: Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Clin Genet 1998;53:447–455.
15.
Hayflick SJ, Eiff MP, Carpenter L, Steinberger J: Primary care physicians’ utilization and perceptions of genetics services. Community Genet 1999;2:129.
16.
Kaback MM: Perspectives in genetic screening. Principles and implications. Int J Technol Assess Health Care 1994;10:592–603.
17.
Wertz DC: Archived specimens: A platform for discussion. Community Genet 1999;2:51–60.
18.
Ulrich CM, Kristal AR, White E, Hunt JR, Durfy SJ, Potter JD: Genetic testing for cancer risk: A population survey on attitudes and intention. Community Genet 1998;1:213–222.
19.
Frank J, Lomax G, Baird PA, Lock M: Genetics and the environment in human health: Sir Geoffrey Rose revisited, in press.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.